National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.

 

NCPE Assessment Process Complete
Rapid review commissioned 29/10/2019
Rapid review completed 02/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avelumab and axitinib compared with the current standard of care.